Emyria has released its latest Company Update, highlighting our:
- Clinical Focus
- Investment Highlights,
- Vision
- Advanced cannabinoid development
- Our Real World Data
- Clinical Program – Including Emyria’sUltra-Pure cannabinoid delivery platform
- Preclinical Pipeline
- Clinical opportunities for MDMA analogues
- Corporate Details & IP
- Leadership and Advisory team
- Patent portfolio
- Corporate structure
You can read the complete December 2022 Company Overview here
